Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Blood (2019) 134 (Supplement_1): 324.

https://doi.org/10.1182/blood-2019-128795

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 4574.

https://doi.org/10.1182/blood-2019-127238

Published: 2019

Journal Articles

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

Blood (2019) 134 (Supplement_1): 4575.

https://doi.org/10.1182/blood-2019-127166

Published: 2019

Journal Articles

High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia

Tobias Dittrich, MD, Martin Schorb, Isabella Haberbosch, MD, Elena Bausch, PhD, Mandy Börmel, Marco Cosenza, PhD, Hartmut Goldschmidt, MD, Carsten Müller-Tidow, MD, Marc S Raab, MD PhD, Ute Hegenbart, MD, Stefan O. Schönland, MD, Yannick Schwab, PhD, Alwin Krämer, MD

Blood (2019) 134 (Supplement_1): 3077.

https://doi.org/10.1182/blood-2019-130713

Published: 2019

Journal Articles

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

Ruben A. Gößmann, Lei Wang, MD, Ming Ni, Mingya Yang, MD, Thomas Luft, Ute Hegenbart, MD, Stefan O. Schönland, MD, Patrick Wuchter, MD, Volker Eckstein, William Hermann Krüger, MD PhD, Ronit Yerushalmi, MD, Katia Beider, Arnon Nagler, MD MSc, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD, Anita Schmitt, MD

Blood (2019) 134 (Supplement_1): 3287.

https://doi.org/10.1182/blood-2019-125049

Published: 2019

Journal Articles

A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations

Tobias Dittrich, MD, Elena Bausch, PhD, Johannes Bausch, PhD, Hartmut Goldschmidt, MD, Ute Hegenbart, MD, Stefan O. Schönland, MD, Marc S Raab, MD PhD, Alwin Krämer, MD

Blood (2019) 134 (Supplement_1): 3379.

https://doi.org/10.1182/blood-2019-129863

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Stefan O Schonland, MD, Tilmann Bochtler, MD, Axel Benner, Marianne Gawlik, Christoph Kimmich, Arnt V Kristen, Jörg Beimler, Anthony D. Ho, MD, Ute Hegenbart, MD

Blood (2013) 122 (21): 1993.

https://doi.org/10.1182/blood.V122.21.1993.1993

Published: 2013

Journal Articles

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

Stefan O Schonland, MD, Ute Hegenbart, MD, Simona Iacobelli, Ph. D., Jennifer Hoek, M Rovira, Guustaaf van Imhoff, G Bandini, Ulf-Henrik Mellqvist, MD, PhD, Veronique Leblond, MD, Kristina Carlson, Samo Zver, MD, Ph.D, Didier Blaise, MD, Emilio Paolo Alessandrino, MD, Laurent Garderet, Nicolaus Kröger, MD

Blood (2013) 122 (21): 417.

https://doi.org/10.1182/blood.V122.21.417.417

Published: 2013

Journal Articles

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Giampaolo Merlini, Vaishali Sanchorawala, Jeffrey A. Zonder, MD, Vishal Kukreti, MD, Stefan O Schonland, MD, Arnaud Jaccard, Angela Dispenzieri, MD, Adam D. Cohen, Deborah Berg, RN, MSN, Guohui Liu, PhD, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, PhD, Giovanni Palladini, Raymond L. Comenzo, MD

Blood (2012) 120 (21): 731.

https://doi.org/10.1182/blood.V120.21.731.731

Published: 2012

Journal Articles

Treatment of AL Amyloidosis with Bendamustine

Giovanni Palladini, Stefan O Schonland, MD, Paolo Milani, Christoph Kimmich, MD, Andrea Foli, Tilmann Bochtler, MD, Giampaolo Merlini, Ute Hegenbart, MD

Blood (2012) 120 (21): 4057.

https://doi.org/10.1182/blood.V120.21.4057.4057

Published: 2012

Journal Articles

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Tilmann Bochtler, MD, Ute Hegenbart, MD, Axel Benner, Dirk Hose, MD, Anja Seckinger, Kai Neben, MD, Sascha Dietrich, MD, Claus R Bartram, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Stefan O Schonland, MD

Blood (2011) 118 (21): 3946.

https://doi.org/10.1182/blood.V118.21.3946.3946

Published: 2011

Journal Articles

Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,

Ute Hegenbart, MD, Stefan O Schonland, MD, Axel Benner, Christina Wunder, Thomas M. Moehler, PD, Dr., Jens Hillengass, Martin Görner, Jana Schlenzka, Kai Neben, MD, Peter Dreger, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2011) 118 (21): 4124.

https://doi.org/10.1182/blood.V118.21.4124.4124

Published: 2011

Journal Articles

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Ashutosh Wechalekar, MD, Stefan O Schonland, MD, Efstathios Kastritis, Philip N Hawkins, Meletios A. Dimopoulos, Paola Russo, MD, Thirusha Lane, RN, Andrea Foli, MD, Darren Foard, RN, Paolo Milani, MD, Lisa Rannigan, RN, Ute Hegenbart, Julian D Gillmore, Giampaolo Merlini, Giovanni Palladini

Blood (2011) 118 (21): 995.

https://doi.org/10.1182/blood.V118.21.995.995

Published: 2011

Journal Articles

Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III)

Stefan O Schonland, MD, Tilmann Bochtler, MD, Anthony D. Ho, MD, Ute Hegenbart, MD

Blood (2010) 116 (21): 1960.

https://doi.org/10.1182/blood.V116.21.1960.1960

Published: 2010

Journal Articles

Validation of the Criteria of Response to Treatment In AL Amyloidosis.

Giovanni Palladini, MD, PhD, Angela Dispenzieri, MD, Morie Abraham A Gertz, MD, Ashutosh Wechalekar, MD, Philip N Hawkins, MD, Stefan O Schonland, MD, Ute Hegenbart, MD, Raymond L. Comenzo, MD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD, Arnaud Jaccard, MD, Catherine Klersy, MD, Giampaolo Merlini, MD

Blood (2010) 116 (21): 1364.

https://doi.org/10.1182/blood.V116.21.1364.1364

Published: 2010

Journal Articles

Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.

Tilmann Bochtler, MD, Stefan O. Schonland, MD, Anna Jauch, PhD, Christiane Heiss, Axel Benner, PhD, Friedrich W. Cremer, MD, Dirk Hose, Marion Moos, PhD, Claus R. Bartram, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Ute Hegenbart, MD

Blood (2007) 110 (11): 2500.

https://doi.org/10.1182/blood.V110.11.2500.2500

Published: 2007

Journal Articles

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Ute Hegenbart, MD, Stefan O. Schonland, MD, Thomas Moehler, MD, Axel Benner, PhD, Sabine Gerull, MD, Martin Goerner, MD, Hans-Joerg Schaefer, MD, Gerlinde Egerer, MD, Peter Dreger, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD

Blood (2006) 108 (11): 3018.

https://doi.org/10.1182/blood.V108.11.3018.3018

Published: 2006

NARROW

Comparison of Different Upfront Transplant Strategies in Multiple Myeloma - a Large Registry Study from Chronic Malignancies Working Party of EBMT

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Safety and Efficacy of Autologous Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients - the Diadem Study from the Chronic Malignancies Working Party of the EBMT

Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017

High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia

Maintaining the Cellular Anti-Viral and Anti-Leukemic Activities in GvHD Patients Undergoing Extracorporeal Photophoresis Therapy

A Semi-Automated Knime-Based Workflow for High Throughput Quantification and Analysis of Centrosome Aberrations

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study

Treatment of AL Amyloidosis with Bendamustine

Gain of 1q21 Is a Cytogenetic Independent Risk Factor in Light Chain Amyloidosis Patients Treated with Melphalan / Dexamethasone As First-Line Therapy,

Comparison of Autologous and Allogeneic Transplantation As Therapy of First Relapse in Patients with Multiple Myeloma - Long-Term Follow up Analysis,

European Collaborative Study of Treatment Outcomes in 347 Patients with Systemic AL Amyloidosis with Mayo Stage III Disease

Efficacy and Toxicity of Dose-Reduced Bortezomib/Dexamethasone Chemotherapy In Patients with High Risk Cardiac Light Chain Amyloidosis (Mayo Clinic stage III)

Validation of the Criteria of Response to Treatment In AL Amyloidosis.

Evaluation of the Cytogenetic Aberration Pattern in AL Amyloidosis Compared to Monoclonal Gammopathies Not Requiring Treatment: Translocation t(11;14) Is More Frequent in AL Amyloidosis.

Polychemotherapy in Combination with Thalidomide Followed by Autologous or Allogeneic Transplantation for Rescue after Autograft or Induction Therapy Failure in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only